| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Oncology: Special SessionsNuclear Oncology Council Young Investigator Award Symposium |
1 Research Center for Charged Particle Therapy, National Institute of Radiological Sciences, Chiba, Japan
76
Objectives: The aim of our study was to evaluate the prognostic value of the change in tumor uptake of 11C-methionin (MET) before and after carbon ion radiotherapy (CIRT) and its correlation with clinical factors such as survival, local control and metastatic rates in patients with carcinoma of the uterine cervix.
Methods: Forty one cases with cancer cervix with both pre- and post-CIRT PET imaging using 11C-methioine were analyzed. Assessment of the change in tumor uptake of MET before and after CIRT was performed in all cases with the semiquantitative tumor-to-normal tissue-ratio (TNR). Kaplan-Meier test was used to analyze the relationship and statistical significance between various factors.
Results: The overall mean survival time was 41.9 months. Significantly better survival (p=0.0046) was detected in patients with post-CIRT reduction of MET uptake of 
39.2% than in patients with percent reduction of < 39.2% (2 year survival rate was 60.6% versus 37.5% respectively). Patients with baseline TNR of 
14.7 had a significantly lower metastatic rate than patients with baseline TNR of > 14.7 (p<0.0001). Patients with post-CIRT TNR of 7.6 had a significantly lower local recurrence rate than patients with post-CIRT TNR of > 7.6 (p<0.0001).
Conclusions: The change in MET uptake before and after CIRT as measured by TNR was an independent predictor of survival in patients with carcinoma of the uterine cervix treated by CIRT. Additional potential value was found for the prediction of metastaitc and local control rates with baseline and post-CIRT TNR respectively.
| ||||||||||||||||||||||||||||
